Spironolactone and resistant hypertension in heart failure with preserved ejection fraction.

about

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study

P2860

Q58765834-6D31FEA5-5462-4115-8605-64CBAFC9584E

P2860

Spironolactone and resistant hypertension in heart failure with preserved ejection fraction.

Item

http://www.wikidata.org/entity/Q49939328

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Spironolactone and resistant h ...... h preserved ejection fraction.

@en

Spironolactone and resistant h ...... h preserved ejection fraction.

@nl

type

Item

label

Spironolactone and resistant h ...... h preserved ejection fraction.

@en

Spironolactone and resistant h ...... h preserved ejection fraction.

@nl

prefLabel

Spironolactone and resistant h ...... h preserved ejection fraction.

@en

Spironolactone and resistant h ...... h preserved ejection fraction.

@nl

P1476

Spironolactone and resistant h ...... h preserved ejection fraction.

@en

P2093

B Claggett

http://www.w3.org/2001/XMLSchema#string

B Pitt

http://www.w3.org/2001/XMLSchema#string

F Zannad

http://www.w3.org/2001/XMLSchema#string

J Liu

http://www.w3.org/2001/XMLSchema#string

O Vardeny

http://www.w3.org/2001/XMLSchema#string

P Rossignol

http://www.w3.org/2001/XMLSchema#string

S Solomon

http://www.w3.org/2001/XMLSchema#string

P2860

Geographic differences in heart failure trials

Spironolactone for heart failure with preserved ejection fraction.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Resistant hypertension: what the cardiologist needs to know.

The double challenge of resistant hypertension and chronic kidney disease.

Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.

Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

P31

scholarly article

P356

10.1093/AJH/HPX210

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29228101

http://www.w3.org/2001/XMLSchema#string

P921

heart failure

P932

5861580

http://www.w3.org/2001/XMLSchema#string

Spironolactone and resistant hypertension in heart failure with preserved ejection fraction.

about

P2860

P2860

Spironolactone and resistant hypertension in heart failure with preserved ejection fraction.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932